Andrew I Rutherford1,2, Eunice Patarata2,3, Sujith Subesinghe1, Kimme L Hyrich4,5, James B Galloway1,2. 1. Academic Rheumatology Department, King's College London, London, UK. 2. Rheumatology Department, King's College Hospital NHS Foundation Trust, London, UK. 3. Autoimmune Disease Unit, Hospital Curry Cabral, Centro Hospitalar Lisboa Central, Lisbon, Portugal, UK. 4. Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester University, Manchester, UK. 5. NIHR Manchester Musculoskeletal Biomedical Research Centre, Central Manchester Foundation Trust, Manchester, UK.
Abstract
Objectives: This analysis set out to estimate the risk of opportunistic infection (OI) among patients with RA by biologic class. Methods: The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis is a prospective observational cohort study established to evaluate safety of biologic therapies. The population included adults commencing biologic therapy for RA. The primary outcome was any serious OI excluding tuberculosis (TB). Event rates were compared across biologic classes using Cox proportional hazards with adjustment for potential confounders identified a priori. Analysis of the incidence of TB was performed separately. Results: In total, 19 282 patients with 106 347 years of follow-up were studied; 142 non-TB OI were identified at a rate of 134 cases/100 000 patient years (pyrs). The overall incidence of OI was not significantly different between the different drug classes; however, the rate of Pneumocystis infection was significantly higher with rituximab than with anti-TNF therapy (adjusted hazard ratio = 3.2, 95% CI: 1.4, 7.5). The rate of TB fell dramatically over the study period (783 cases/100 000 pyrs in 2002 to 38 cases/100 000 pyrs in 2015). The incidence of TB was significantly lower among rituximab users than anti-TNF users, with 12 cases/100 000 pyrs compared with 65 cases/100 000 pyrs. Conclusions: The overall rate of OI was not significantly different between drug classes; however, a subtle difference in the pattern of OI was seen between the cohorts. Patient factors such as age, gender and comorbidity were the most important predictors of OI.
Objectives: This analysis set out to estimate the risk of opportunistic infection (OI) among patients with RA by biologic class. Methods: The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis is a prospective observational cohort study established to evaluate safety of biologic therapies. The population included adults commencing biologic therapy for RA. The primary outcome was any serious OI excluding tuberculosis (TB). Event rates were compared across biologic classes using Cox proportional hazards with adjustment for potential confounders identified a priori. Analysis of the incidence of TB was performed separately. Results: In total, 19 282 patients with 106 347 years of follow-up were studied; 142 non-TB OI were identified at a rate of 134 cases/100 000 patient years (pyrs). The overall incidence of OI was not significantly different between the different drug classes; however, the rate of Pneumocystis infection was significantly higher with rituximab than with anti-TNF therapy (adjusted hazard ratio = 3.2, 95% CI: 1.4, 7.5). The rate of TB fell dramatically over the study period (783 cases/100 000 pyrs in 2002 to 38 cases/100 000 pyrs in 2015). The incidence of TB was significantly lower among rituximab users than anti-TNF users, with 12 cases/100 000 pyrs compared with 65 cases/100 000 pyrs. Conclusions: The overall rate of OI was not significantly different between drug classes; however, a subtle difference in the pattern of OI was seen between the cohorts. Patient factors such as age, gender and comorbidity were the most important predictors of OI.
Authors: Caterina Palleria; Luigi Iannone; Christian Leporini; Rita Citraro; Antonia Manti; Maurizio Caminiti; Pietro Gigliotti; Rosa Daniela Grembiale; Massimo L'Andolina; Giuseppe Muccari; Maria Diana Naturale; Domenico Olivo; Giuseppa Pagano Mariano; Roberta Pellegrini; Giuseppe Varcasia; Karim Abdalla; Emilio Russo; Francesco Ursini; Giovambattista De Sarro Journal: PLoS One Date: 2018-10-24 Impact factor: 3.240
Authors: Maria Antonietta Barbieri; Giuseppe Cicala; Paola Maria Cutroneo; Elisabetta Gerratana; Caterina Palleria; Caterina De Sarro; Ada Vero; Luigi Iannone; Antonia Manti; Emilio Russo; Giovambattista De Sarro; Fabiola Atzeni; Edoardo Spina Journal: J Clin Med Date: 2020-04-24 Impact factor: 4.241
Authors: Leona E Ling; Jan L Hillson; Renger G Tiessen; Tjerk Bosje; Mattheus Paulus van Iersel; Darrell J Nix; Lynn Markowitz; Nicholas A Cilfone; Jay Duffner; James B Streisand; Anthony M Manning; Santiago Arroyo Journal: Clin Pharmacol Ther Date: 2018-12-04 Impact factor: 6.875
Authors: Silvia Sánchez-Ramón; Lidia Fernández-Paredes; Paula Saz-Leal; Carmen M Diez-Rivero; Juliana Ochoa-Grullón; Concepción Morado; Pilar Macarrón; Cristina Martínez; Virginia Villaverde; Antonia Rodríguez de la Peña; Laura Conejero; Keyla Hernández-Llano; Gustavo Cordero; Miguel Fernández-Arquero; Benjamin Fernández- Gutierrez; Gloria Candelas Journal: Front Immunol Date: 2021-06-04 Impact factor: 7.561